Comprehensive murine study confirms safety, complementing previous efficacy data on ActivePure’s continuous air and surface decontamination technology

ActivePure Medical, a division of AP Sciences Group, LLC, a global provider of cutting-edge, continuous air and surface decontamination technology, today announced results from a safety study of its ActivePure Advanced Photohydrolysis Technology. The study, published in PLOS One, provides direct and comprehensive evidence of the safety of ActivePure’s proprietary photohydrolysis technology, for use in occupied indoor spaces.1 These findings support and encourage the continued adoption of this proven technology for reducing airborne and surface pathogens.

There is a pressing need for effective, continuous air cleaning and surface disinfection technologies, highlighted by recent public health crises. ActivePure Technology, as implemented in the Induct Guardian Series, has already demonstrated significant efficacy in reducing pathogens with a recent study published in the American Journal of Infection Control showing 96-99% reduction in methicillin-resistant Staphylococcus aureus (MRSA) and 70-71% decreases in healthcare-associated infections in hospital settings over 12-21 months.2

This newly published data complements previous efficacy studies by demonstrating the safety of continuous use of the ActivePure Advanced Photohydrolysis Technology. The study utilized murine subjects due to their physiological similarities to humans. The 90-day safety study used a C57BL murine model, a strain chosen for its sensitivity to airborne substances and pronounced inflammatory responses. The mice were exposed to therapeutic levels of ActivePure’s Advanced Photohydrolysis Technology, with researchers monitoring behavior, weight gain, food consumption, blood chemistry and hematology, as well as conducting detailed histological examinations of respiratory tissues.

“This study provides detailed, direct evidence of the safety of advanced photohydrolysis technology using a mammalian model,” said Claude P. Selitrennikoff, Ph.D., the lead study author. “Thorough examination of respiratory tissues revealed no adverse effects on physiology, even after continuous 90-day exposure. In an era marked by emerging global health threats, innovations like ActivePure Advanced Photohydrolysis Technology are essential for creating safer indoor environments.”

Key findings include:

  • No observable differences in behavior, weight gain, or food consumption between exposed and control mice
  • Normal blood chemistry and hematology values in exposed mice
  • No evidence of tissue damage, inflammation, or abnormalities in the respiratory tract of exposed mice

“ActivePure Technology has established through FDA clearance, lab testing, and real-world outcomes, that it is highly effective at remediating the six most infectious forms of pathogens,” said Joseph, P. Urso, CEO of AP Sciences Group, LLC. “The results of this research study bring further assurance to questions of safety that should be asked regarding every technology being used to protect health. We are delighted to share this study and build confidence, not only in the efficacy of ActivePure, but also in the peace of mind that can come from its implementation.”

About ActivePure Medical

ActivePure Medical, a division of AP Sciences Group, LLC, is a global leader in proactive, continuous surface and air decontamination systems for healthcare. The company's proprietary ActivePure Advanced Photohydrolysis Technology safely neutralizes indoor contaminants in the air and on surfaces. This scientifically adapted technology replicates the natural atmospheric cleansing processes, providing continuous, persistent protection against environmental contamination risks without relying on human intervention. ActivePure Technology effectively reduces many common volatile organic compounds (VOCs) and operates without producing harmful ozone, making it safe for continuous use in occupied spaces. Initially developed for space exploration, it has evolved to reduce exposure to pathogens, including RNA and DNA viruses, bacteria, and molds, by up to 99.9% in the air and on surfaces. ActivePure Technology has proven effective across various settings, including acute care, long-term care facilities, and commercial buildings. ActivePure Technology is a key component in the ActivePure Medical Guardian, an FDA 510(k)-cleared Class II Medical Device. For more information, please visit ActivePure.com/healthcare.

About ActivePure Advanced Photohydrolysis Technology

ActivePure Technology is a pioneering approach to environmental decontamination. The technology features a honeycomb matrix with a proprietary coating and a specialized UV bulb, facilitating a photolysis reaction with ambient humidity, which produces powerful hydrogen and oxygen-based oxidative molecules, effective at remediating a broad spectrum of contaminants. This proactive process targets both air and surface contamination, providing continuous, 24/7 protection. Studies have confirmed its efficacy, demonstrating up to 99% reduction in surface methicillin-resistant Staphylococcus aureus (MRSA) and fungi, and significant decreases in healthcare-associated infections (HAIs).

__________________________ 1 Selitrennikoff CP, et al. (2024) Evaluate the safety of a novel photohydrolysis technology used to clean and disinfect indoor air: A murine study. PLoS ONE. 19(10):e0307031. doi.10.1371/journal.pone.0307031

2 Trosch, K et al. (2024) The effects of a novel, continuous disinfectant technology on methicillin-resistant Staphylococcus aureus (MRSA), fungi, and aerobic bacteria in 2 separate intensive care units in 2 different states: An experimental design with observed impact on health care associated infections (HAIs). Am. J. Infect. Control. 52(8):884-892. doi:10.1016/j.ajic.2024.03.013

Media: Ben Shannon ICR Westwicke ActivePurePR@westwicke.com